Combining cell-penetrating and cancer-targeting peptides with DNA nanostructures created a drug delivery system that improved tumor targeting, stability, and anti-cancer effectiveness in mice.
Dual drug + gene therapy in one nanostructurePeptide-assembled DNA nanotubes co-delivered doxorubicin and KRAS siRNA, combining chemotherapy with gene silencing in a mouse tumor model
What the researchers found
RGD-TAT peptides replaced conventional magnesium ions for DNA nanostructure self-assembly while adding cancer targeting and cell penetration capabilities. The peptide/DNA nanostructures demonstrated high membrane penetration, integrin-mediated cancer cell targeting, and lysosome escape. Using protease-resistant D-type peptides significantly enhanced structural and serum stability.
In a mouse tumor model, the NTD-RGD-TAT-DOX-siKRAS nanotube showed excellent tumor accumulation and anti-cancer effects by simultaneously delivering doxorubicin and suppressing KRAS oncogene expression, combining chemotherapy with gene therapy in a single platform.
Why it matters
DNA nanotechnology has enormous potential for precision drug delivery, but instability and poor cell entry have limited clinical use. By replacing simple ions with functional peptides, this approach solves multiple problems simultaneously — the peptides both hold the structure together and actively target it to cancer cells. This could accelerate the translation of DNA nanomedicine to the clinic.
How the study worked
Cationic peptides (RGD-TAT) were used to assemble DNA nanostructures without magnesium. In vitro studies assessed cellular uptake, membrane penetration, integrin targeting, and lysosome escape. Stability was tested with both L-type and protease-resistant D-type peptides. In vivo proof of concept used doxorubicin and KRAS siRNA-loaded nanotubes in an immunodeficient mouse tumor model to assess tumor accumulation and anti-cancer efficacy.
What this study cannot tell us
The in vivo study used an immunodeficient mouse model, which doesn't capture immune system interactions. Long-term toxicity and biodistribution were not reported. The scalability of manufacturing peptide/DNA nanostructures for clinical use remains unclear. The specific tumor type and KRAS-dependent mechanism may not generalize to all cancers.
How to read the evidence
This is a preclinical proof-of-concept study with both in vitro and in vivo (mouse) data. While the approach is innovative and the results promising, it remains early-stage with no human data or clinical development reported.
When this study was published
Published in 2025, this study represents the current frontier of peptide-DNA nanotechnology for cancer drug delivery.
The bigger picture
This work sits at the intersection of three cutting-edge fields: DNA nanotechnology, peptide engineering, and combination cancer therapy. The ability to use peptides as both structural components and functional elements in DNA nanodevices represents a versatile platform that could be adapted for many different cancer types and therapeutic combinations.
Questions still open
- Can this peptide/DNA platform be adapted for immunotherapy delivery or combined with immune checkpoint inhibitors?
- How does the system perform in immunocompetent models where immune clearance may reduce efficacy?
- What is the manufacturing scalability and cost for clinical translation of these peptide-assembled DNA nanostructures?
Common questions
What is a DNA nanostructure and how can it deliver drugs?
Why use peptides instead of magnesium to build these structures?
Read the original research
Magnesium-Free Assembly of Cationic Peptide/DNA Nanostructures with Defined Geometries for Anticancer Drug Delivery.
ACS applied materials & interfaces, 17(27), 38971-38984
Citation
Gu, Peng-Cheng; Chen, Chun-Fa; Ma, Lian-Ju; Wang, Lu; Bai, Yan; Yang, Jia-Qi; Zhu, Shu; Li, Quan; Bai, Jia-Hao; Sun, Yang-Yi; Chen, Xin-Hong; Jiang, Xin-Ya; Liu, Qian; Qian, Hang. (2025). Magnesium-Free Assembly of Cationic Peptide/DNA Nanostructures with Defined Geometries for Anticancer Drug Delivery.. ACS applied materials & interfaces, 17(27), 38971-38984. https://doi.org/10.1021/acsami.5c07816